Cargando…

Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial

BACKGROUND: Although it has been shown that acute beta-blocker administration may reduce the presence or severity of myocardial perfusion defects with dipyridamole stress, little information is available about the potential effect of chronic beta-blocker treatment on the sensitivity of dipyridamole...

Descripción completa

Detalles Bibliográficos
Autores principales: Fallahi, Babak, Beiki, Davood, Akbarpour, Saeed, Gholamrezanezhad, Ali, Fard-Esfahani, Armaghan, Akhzari, Fariba, Izadyar, Sina, Esmaeli, Javad, Saghari, Mohsen, Eftekhari, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565929/
https://www.ncbi.nlm.nih.gov/pubmed/23351617
http://dx.doi.org/10.1186/2008-2231-21-8
_version_ 1782258493369090048
author Fallahi, Babak
Beiki, Davood
Akbarpour, Saeed
Gholamrezanezhad, Ali
Fard-Esfahani, Armaghan
Akhzari, Fariba
Izadyar, Sina
Esmaeli, Javad
Saghari, Mohsen
Eftekhari, Mohammad
author_facet Fallahi, Babak
Beiki, Davood
Akbarpour, Saeed
Gholamrezanezhad, Ali
Fard-Esfahani, Armaghan
Akhzari, Fariba
Izadyar, Sina
Esmaeli, Javad
Saghari, Mohsen
Eftekhari, Mohammad
author_sort Fallahi, Babak
collection PubMed
description BACKGROUND: Although it has been shown that acute beta-blocker administration may reduce the presence or severity of myocardial perfusion defects with dipyridamole stress, little information is available about the potential effect of chronic beta-blocker treatment on the sensitivity of dipyridamole myocardial perfusion imaging (DMPI). METHODS: As a randomized clinical trial, one hundred twenty patients (103 male and 17 female) with angiographically confirmed CAD who were on long-term beta blocker therapy (≥3 months) enrolled in a randomized clinical trial study. The patients were allocated into two groups: Group A (n=60) in whom the beta-blocker agent was discontinued for 72h before DMPI and Group B (n=60) without discontinuation of beta-blockers prior to DMPI. RESULTS: No significant difference was noted between the groups concerning age, sex, type of the injected radiotracer and number of involved coronary vessels. The mean rank of total perfusion scores for whole myocardium (irrespective of reversibility or irreversibility) in group B was not significantly different from that of group A, (65.75 vs. 55.25, P=0.096). Regarding the only irreversible perfusion defects, the mean rank of perfusion score in group B was higher than that of group A for whole myocardium (72 vs. 49, P=0.0001); however, no difference was noted between two groups for only reversible perfusion defects (61.0 vs. 60.0, P=0.898). The overall sensitivity of DMPI for the diagnosis of CAD in group A (91.7%) was not statistically different from group B (90%). CONCLUSION: Beta-blocker withholding before DMPI did not generally affect the sensitivity of the test for the diagnostic purposes in our study. Thus, beta-blocker withdrawal for just the purpose of diagnostic imaging is not mandatory particularly when medication discontinuation may cause the patients to face increased risk of heart events.
format Online
Article
Text
id pubmed-3565929
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35659292013-02-11 Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial Fallahi, Babak Beiki, Davood Akbarpour, Saeed Gholamrezanezhad, Ali Fard-Esfahani, Armaghan Akhzari, Fariba Izadyar, Sina Esmaeli, Javad Saghari, Mohsen Eftekhari, Mohammad Daru Research Article BACKGROUND: Although it has been shown that acute beta-blocker administration may reduce the presence or severity of myocardial perfusion defects with dipyridamole stress, little information is available about the potential effect of chronic beta-blocker treatment on the sensitivity of dipyridamole myocardial perfusion imaging (DMPI). METHODS: As a randomized clinical trial, one hundred twenty patients (103 male and 17 female) with angiographically confirmed CAD who were on long-term beta blocker therapy (≥3 months) enrolled in a randomized clinical trial study. The patients were allocated into two groups: Group A (n=60) in whom the beta-blocker agent was discontinued for 72h before DMPI and Group B (n=60) without discontinuation of beta-blockers prior to DMPI. RESULTS: No significant difference was noted between the groups concerning age, sex, type of the injected radiotracer and number of involved coronary vessels. The mean rank of total perfusion scores for whole myocardium (irrespective of reversibility or irreversibility) in group B was not significantly different from that of group A, (65.75 vs. 55.25, P=0.096). Regarding the only irreversible perfusion defects, the mean rank of perfusion score in group B was higher than that of group A for whole myocardium (72 vs. 49, P=0.0001); however, no difference was noted between two groups for only reversible perfusion defects (61.0 vs. 60.0, P=0.898). The overall sensitivity of DMPI for the diagnosis of CAD in group A (91.7%) was not statistically different from group B (90%). CONCLUSION: Beta-blocker withholding before DMPI did not generally affect the sensitivity of the test for the diagnostic purposes in our study. Thus, beta-blocker withdrawal for just the purpose of diagnostic imaging is not mandatory particularly when medication discontinuation may cause the patients to face increased risk of heart events. BioMed Central 2013-01-15 /pmc/articles/PMC3565929/ /pubmed/23351617 http://dx.doi.org/10.1186/2008-2231-21-8 Text en Copyright ©2012 Fallahi et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Fallahi, Babak
Beiki, Davood
Akbarpour, Saeed
Gholamrezanezhad, Ali
Fard-Esfahani, Armaghan
Akhzari, Fariba
Izadyar, Sina
Esmaeli, Javad
Saghari, Mohsen
Eftekhari, Mohammad
Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial
title Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial
title_full Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial
title_fullStr Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial
title_full_unstemmed Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial
title_short Withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? A randomized clinical trial
title_sort withholding or continuing beta-blocker treatment before dipyridamole myocardial perfusion imaging for the diagnosis of coronary artery disease? a randomized clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565929/
https://www.ncbi.nlm.nih.gov/pubmed/23351617
http://dx.doi.org/10.1186/2008-2231-21-8
work_keys_str_mv AT fallahibabak withholdingorcontinuingbetablockertreatmentbeforedipyridamolemyocardialperfusionimagingforthediagnosisofcoronaryarterydiseasearandomizedclinicaltrial
AT beikidavood withholdingorcontinuingbetablockertreatmentbeforedipyridamolemyocardialperfusionimagingforthediagnosisofcoronaryarterydiseasearandomizedclinicaltrial
AT akbarpoursaeed withholdingorcontinuingbetablockertreatmentbeforedipyridamolemyocardialperfusionimagingforthediagnosisofcoronaryarterydiseasearandomizedclinicaltrial
AT gholamrezanezhadali withholdingorcontinuingbetablockertreatmentbeforedipyridamolemyocardialperfusionimagingforthediagnosisofcoronaryarterydiseasearandomizedclinicaltrial
AT fardesfahaniarmaghan withholdingorcontinuingbetablockertreatmentbeforedipyridamolemyocardialperfusionimagingforthediagnosisofcoronaryarterydiseasearandomizedclinicaltrial
AT akhzarifariba withholdingorcontinuingbetablockertreatmentbeforedipyridamolemyocardialperfusionimagingforthediagnosisofcoronaryarterydiseasearandomizedclinicaltrial
AT izadyarsina withholdingorcontinuingbetablockertreatmentbeforedipyridamolemyocardialperfusionimagingforthediagnosisofcoronaryarterydiseasearandomizedclinicaltrial
AT esmaelijavad withholdingorcontinuingbetablockertreatmentbeforedipyridamolemyocardialperfusionimagingforthediagnosisofcoronaryarterydiseasearandomizedclinicaltrial
AT sagharimohsen withholdingorcontinuingbetablockertreatmentbeforedipyridamolemyocardialperfusionimagingforthediagnosisofcoronaryarterydiseasearandomizedclinicaltrial
AT eftekharimohammad withholdingorcontinuingbetablockertreatmentbeforedipyridamolemyocardialperfusionimagingforthediagnosisofcoronaryarterydiseasearandomizedclinicaltrial